Cargando…

Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis

BACKGROUND: Visceral leishmaniasis (VL) is a chronic debilitating disease endemic in tropical and subtropical areas, caused by protozoan parasites of the genus Leishmania. Annually, it is estimated the occurrence of 0.2 to 0.4 million new cases of the disease worldwide. Considering the lack of an ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castro, Renata A. O., Silva-Barcellos, Neila M., Licio, Carolina S. A., Souza, Janine B., Souza-Testasicca, Míriam C., Ferreira, Flávia M., Batista, Mauricio A., Silveira-Lemos, Denise, Moura, Sandra L., Frézard, Frédéric, Rezende, Simone A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126701/ https://www.ncbi.nlm.nih.gov/pubmed/25105501 http://dx.doi.org/10.1371/journal.pone.0104055

Ejemplares similares

Ascorbate peroxidase overexpression protects Leishmania braziliensis against trivalent antimony effects
por: Moreira, Douglas de Souza, et al.
Publicado: (2018)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
por: Maristany Bosch, Marta, et al.
Publicado: (2021)

Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male
por: Das, PC, et al.
Publicado: (2014)

Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver
por: Lopes, Tamara C. M., et al.
Publicado: (2018)

Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?
por: Perry, Meghan R., et al.
Publicado: (2011)

Increased thiol levels in antimony-resistant Leishmania infantum isolated from treatment-refractory visceral leishmaniasis in Brazil
por: Magalhães, Lucas S, et al.
Publicado: (2018)

Mannosyltransferase (GPI-14) overexpression protects promastigote and amastigote forms of Leishmania braziliensis against trivalent antimony
por: Ribeiro, Christiana Vargas, et al.
Publicado: (2019)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

Comparative analysis of the transcriptional responses of five Leishmania species to trivalent antimony
por: Medina, Julián, et al.
Publicado: (2021)

Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy
por: Mukherjee, Sandip, et al.
Publicado: (2020)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India
por: Stauch, Anette, et al.
Publicado: (2012)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis
por: Romanelli, Maiara Maria, et al.
Publicado: (2019)

Antimony resistance during Visceral Leishmaniasis: A possible consequence of serial mutations in ABC transporters of Leishmania species
por: Sinha, Sukrat, et al.
Publicado: (2011)

Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study
por: Perry, Meghan R., et al.
Publicado: (2015)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
por: Jamshidi, Sh, et al.
Publicado: (2011)

HISTORICAL SERIES OF PATIENTS WITH VISCERAL LEISHMANIASIS TREATED WITH MEGLUMINE ANTIMONIATE IN A HOSPITAL FOR TROPICAL DISEASES, MACEIÓ-AL, BRAZIL
por: Silveira, Lindon Johoson Diniz, et al.
Publicado: (2015)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Gain-of-function STAT1 mutation and visceral leishmaniasis
por: Lyra, Paula Teixeira, et al.
Publicado: (2022)

Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility
por: Santi, Ana Maria Murta, et al.
Publicado: (2021)

Visceral leishmaniasis (kala-azar) and pregnancy.
por: Figueiró-Filho, Ernesto Antonio, et al.
Publicado: (2004)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony()
por: Moreira, Douglas S., et al.
Publicado: (2013)

Peg-Grafted Liposomes for L-Asparaginase Encapsulation
por: de Souza Guimarães, Marina, et al.
Publicado: (2022)

Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes
por: Toledo-Machado, Christina Monerat, et al.
Publicado: (2015)

Canine visceral leishmaniasis in the Northeast Region of Brazil
por: Brito, Flávio Gonçalves, et al.
Publicado: (2016)

Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
por: Bezerra-Souza, Adriana, et al.
Publicado: (2019)

Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia–Reperfusion Injury
por: Davis, Janelle L., et al.
Publicado: (2016)

Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
por: Haldar, Arun Kumar, et al.
Publicado: (2011)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_93ck1qhjcr4bojql8vnneljg4p